Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 9
- Registration Number
- NCT01469338
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01447225
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2017-11-21
- Target Recruit Count
- 14
- Registration Number
- NCT01437488
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2024-03-27
- Target Recruit Count
- 20
- Registration Number
- NCT01420250
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- howard safran
- Target Recruit Count
- 15
- Registration Number
- NCT01365130
- Locations
- 🇺🇸
Memorial Hospital, Pawtucket, Rhode Island, United States
🇺🇸Brown University Oncology Research Group, Providence, Rhode Island, United States
🇺🇸Roger Williams, Providence, Rhode Island, United States
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 984
- Registration Number
- NCT01254279
- Locations
- 🇮🇹
Investigational Site Number 380-005, Genova, Italy
🇦🇺Investigational Site Number 036002, Camperdown, Australia
🇦🇺Investigational Site Number 036020, Campbelltown, Australia
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT01083615
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2013-09-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 19
- Registration Number
- NCT01001221
- Locations
- 🇺🇸
Investigational Site Number 840004, Philadelphia, Pennsylvania, United States
🇺🇸Investigational Site Number 840005, Cincinnati, Ohio, United States
🇺🇸Investigational Site Number 840001, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.